http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020368338-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7df267c0e21d6b0ad2a3490807c38477 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_01ffe6757d638a728acb8def4e30c148 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6031 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-572 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55566 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55516 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-70 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-646 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4748 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001153 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08 |
filingDate | 2018-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ab0236cc8641c40935ad6c311473a07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b2583f73e491be16f0dce9ef8dd5f724 |
publicationDate | 2020-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | US-2020368338-A1 |
titleOfInvention | Conjugate of wt1-derived peptides and composition comprising the same |
abstract | The present disclosure includes a compound of formula (1): n n n n n n n n n n wherein cancer antigen peptide A is an MHC class I-restricted peptide consisting of 7 to 30 amino acid residues and containing at least one cysteine residue, wherein the cysteine residue of the cancer antigen peptide A binds to R 1 via a disulfide bond; and n R 1 is hydrogen, a group of formula (2), the group of formula (3), or cancer antigen peptide D, n wherein the group of formula 2 is n n n n n n n n n n n n wherein X a and Y d independently represent a single bond or a divalent peptide group consisting of 1 to 4 amino acid residues, provided that the sum of the number of amino acid residues in X a and Y a is an integer of 0 to 4, and n the cancer antigen peptide B is an MHC class II-restricted peptide consisting of 9 to 30 amino acid residues, wherein the amino group of the N-terminal amino acid of the cancer antigen peptide B binds to Y a in the formula (2), and the carbonyl group of the C-terminal amino acid of the cancer antigen peptide B binds to the hydroxyl group in the formula (2), and the formula (1) and the formula (2) binds via a disulfide bond, n the group of formula (3) is n n n n n n n n n n n n wherein X b and Y b independently represent a single bond or a divalent peptide group consisting of 1 to 4 amino acid residues, provided that the sum of the number of amino acid residues in X b and Y b is an integer of 0 to 4, and n the cancer antigen peptide C is an MHC class II-restricted peptide consisting of 9 to 30 amino acid residues, wherein the carbonyl group of the C-terminal amino acid of the cancer antigen peptide C binds to X b in the formula (3), and the amino group of the N-terminal amino acid of the cancer antigen peptide C binds to the hydrogen atom in the formula (3), and the formula (1) and the formula (3) binds via a disulfide bond, and n the cancer antigen peptide D is an MHC class II-restricted peptide consisting of 9 to 30 amino acid residues and containing at least one cysteine, wherein the cysteine residue of the cancer antigen peptide D binds to R 1 via a disulfide bond; n or a pharmaceutically acceptable salt thereof. |
priorityDate | 2017-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 820.